Effects of supervised exercise therapy and non-supervised exercise therapy for patients with arteriosclerosis obliterans after intravascular intervention.

Effects of supervised exercise therapy and non-supervised exercise therapy for patients with arteriosclerosis obliterans after intravascular intervention. - Effects of exercise therapy for patients with arteriosclerosis obliterans.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006481

Enrollment

Registered

2011-10-13

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis obliterans

Interventions

Supervised exercise therapy Non-supervised exercise therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with arteriosclerosis obliterans who have intermittent claudication with the indication of intravascular intervention.

Exclusion criteria

Exclusion criteria: Patients were excluded if they were: on chronic hemodialysis. with severe coronary artery stenosis. Breast-feeding women or with a chance of pregnancy. with side effects of antiplatelets. with severe liver and/or renal dysfunction. with malignant disease in the past five years. with reflactory ulcer. not able to walk because of orthopedic disease or others. with diabetic proliferative retinopathy. not recommended for exercise therapy according to based on the Japanese guideline of cardiac rehabilitation.

Design outcomes

Primary

Measure	Time frame
1, Evaluation of intermittent claudication (treadmill exercise test, six-minutes walk distance) 2, subjective symptoms (SF36, WIQ score) 3, Ankle brachial index 4, Intima media thickness of the carotid artery 5, flow mediated vasodilatation 6, Labo data (coronary risk factors, oxidative stress, and other biomarkers) 7, Whether unfortunate events occured; all death, acute myocardiac infarction, coronary intervention, peripheral intervention, cerebrovascular disease, bleeding complications and other adverse events.	—

Measure

Time frame

1, Evaluation of intermittent claudication (treadmill exercise test, six-minutes walk distance) 2, subjective symptoms (SF36, WIQ score) 3, Ankle brachial index 4, Intima media thickness of the carotid artery 5, flow mediated vasodilatation 6, Labo data (coronary risk factors, oxidative stress, and other biomarkers) 7, Whether unfortunate events occured; all death, acute myocardiac infarction, coronary intervention, peripheral intervention, cerebrovascular disease, bleeding complications and other adverse events.

—

Countries

Japan

Contacts

Public ContactSaeko Yamasaki

Shinshu University Hospital Department of cardiology

saeko@shinshu-u.ac.jp0263-37-3486

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026